As Asian markets navigate a complex landscape of regulatory changes and economic shifts, investors are increasingly focused on identifying stocks that may be priced below their intrinsic value. In this environment, a good stock is often characterized by strong fundamentals and resilience to market fluctuations, making it an attractive option for those seeking potential opportunities in undervalued equities.
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Zhongji Innolight (SZSE:300308) | CN¥581.90 | CN¥1151.94 | 49.5% |
| Wacom (TSE:6727) | ¥794.00 | ¥1547.14 | 48.7% |
| Suzhou Shihua New Material Technology (SHSE:688093) | CN¥39.65 | CN¥78.65 | 49.6% |
| Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) | HK$429.40 | HK$840.69 | 48.9% |
| Shanghai MicroPort MedBot (Group) (SEHK:2252) | HK$30.92 | HK$61.38 | 49.6% |
| Plus Alpha ConsultingLtd (TSE:4071) | ¥2330.00 | ¥4645.31 | 49.8% |
| PharmaResearch (KOSDAQ:A214450) | ₩428000.00 | ₩846322.49 | 49.4% |
| Ningxia Building Materials GroupLtd (SHSE:600449) | CN¥13.22 | CN¥26.04 | 49.2% |
| Komehyo HoldingsLtd (TSE:2780) | ¥3415.00 | ¥6750.42 | 49.4% |
| Chifeng Jilong Gold MiningLtd (SHSE:600988) | CN¥38.39 | CN¥76.15 | 49.6% |
Let's uncover some gems from our specialized screener.
Overview: Chow Tai Fook Jewellery Group Limited is an investment holding company that manufactures and sells jewelry products in Mainland China, Hong Kong, Macau, and internationally with a market cap of HK$135.25 billion.
Operations: The company's revenue is primarily derived from Mainland China, contributing HK$73.75 billion, and from Hong Kong, Macau, and other markets with HK$16.58 billion.
Estimated Discount To Fair Value: 34.1%
Chow Tai Fook Jewellery Group is trading at 34.1% below its estimated fair value, indicating it may be undervalued based on cash flows. Despite slower revenue growth forecasts compared to the Hong Kong market, earnings are expected to grow significantly over the next three years. Recent strategic expansions into Southeast Asia and brand transformation efforts underscore potential for sustainable growth, though current dividends are not well covered by earnings or free cash flows.
Overview: Shanghai MicroPort MedBot (Group) Co., Ltd. operates in the medical technology sector, focusing on the development and commercialization of surgical robots, with a market cap of HK$31.89 billion.
Operations: The company generates revenue from the sale of medical devices, amounting to CN¥333.70 million.
Estimated Discount To Fair Value: 49.6%
Shanghai MicroPort MedBot is trading at 49.6% below its estimated fair value, highlighting potential undervaluation based on cash flows. The company's revenue is projected to grow significantly faster than the Hong Kong market, with expectations of profitability within three years. Recent approval of the UniPath robotic system by China's NMPA and strong commercial performance of its Toumai surgical robot underscore robust product innovation and adoption, supporting future cash flow growth despite recent share price volatility.
Overview: Shanjin International Gold Co., Ltd. engages in the exploration, mining, and trading of precious and non-ferrous metal ores in China with a market capitalization of CN¥96.54 billion.
Operations: Shanjin International Gold Co., Ltd. generates revenue through its operations in the exploration, mining, and trading of precious and non-ferrous metal ores within China.
Estimated Discount To Fair Value: 45.9%
Shanjin International Gold is trading at 45.9% below its estimated fair value, suggesting significant undervaluation based on cash flows. Despite earnings growth slower than the market, the company's revenue and net income have shown strong year-on-year increases, with revenue reaching CN¥14.99 billion for nine months in 2025. The company completed a share buyback of 1,834,929 shares worth CN¥34.09 million by December 2025, reflecting strategic capital management amidst its unstable dividend history.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Contact Us
Contact Number : +852 3852 8500
English